STOCK TITAN

GeneDx (WGS) CFO exercises 16,250 RSUs, sells shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. He exercised 16,250 restricted stock units, receiving the same number of Class A Common Stock shares for no cash cost. On the same date, he sold 8,818 shares of Class A Common Stock in several open-market transactions at weighted average prices in the low-to-mid $60s per share. According to the disclosure, these sales were executed solely to cover tax withholding obligations from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades. After these transactions, he beneficially owned 34,580 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 93,173 additional shares and options to purchase up to 25,906 shares, all vesting over time according to their terms.

Positive

  • None.

Negative

  • None.
Insider Feeley Kevin
Role CHIEF FINANCIAL OFFICER
Sold 8,818 shs ($557K)
Type Security Shares Price Value
Exercise Restricted Stock Unit 16,250 $0.00 --
Exercise Class A Common Stock 16,250 $0.00 --
Sale Class A Common Stock 2,485 $61.2909 $152K
Sale Class A Common Stock 961 $62.3319 $60K
Sale Class A Common Stock 2,520 $63.2791 $159K
Sale Class A Common Stock 995 $64.5993 $64K
Sale Class A Common Stock 1,857 $65.2143 $121K
Holdings After Transaction: Restricted Stock Unit — 32,500 shares (Direct); Class A Common Stock — 43,398 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.93 to $62.91 per share, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.96 to $63.955 per share, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.99 to $64.96 per share, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.61 per share, inclusive. Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 34,580 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 93,173 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. 25% of the total award vested or vests annually, with the first tranche vested on March 26, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
RSUs exercised 16,250 units Restricted stock units converted to Class A Common Stock
Shares sold 8,818 shares Class A Common Stock sold to cover tax withholding
Sale price range (low) $60.93–$61.91 Weighted average range for one group of sale transactions
Sale price range (high) $65.00–$65.61 Weighted average range for another group of sale transactions
Shares held after sale 34,580 shares Class A Common Stock beneficially owned post-transaction
Unvested RSUs 93,173 units Contingent rights to receive Class A Common Stock
Stock options 25,906 shares Options to purchase Class A Common Stock outstanding
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
sell to cover financial
"The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction..."
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficially owned financial
"34,580 shares of Class A Common Stock beneficially owned by the Reporting Person..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share..."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feeley Kevin

(Last)(First)(Middle)
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST., NORTH TOWER, 6TH FLOOR

(Street)
STAMFORD CONNECTICUT 06902

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock03/26/2026M16,250A$0(1)43,398D
Class A Common Stock03/26/2026S(2)2,485D$61.2909(3)40,913D
Class A Common Stock03/26/2026S(2)961D$62.3319(4)39,952D
Class A Common Stock03/26/2026S(2)2,520D$63.2791(5)37,432D
Class A Common Stock03/26/2026S(2)995D$64.5993(6)36,437D
Class A Common Stock03/26/2026S(2)1,857D$65.2143(7)34,580(8)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)03/26/2026M16,250 (9) (9)Class A Common Stock16,250$032,500D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.93 to $62.91 per share, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.96 to $63.955 per share, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.99 to $64.96 per share, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.61 per share, inclusive.
8. Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 34,580 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 93,173 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
9. 25% of the total award vested or vests annually, with the first tranche vested on March 26, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
/s/ Bridget Brown, Attorney-in-Fact03/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did GeneDx (WGS) CFO Kevin Feeley report in this Form 4 filing?

He reported exercising 16,250 restricted stock units into Class A Common Stock and related share sales. The filing shows routine equity compensation activity linked to RSU vesting, rather than a discretionary change in his investment position in GeneDx Holdings Corp.

How many GeneDx (WGS) shares did the CFO sell, and for what purpose?

He sold a total of 8,818 shares of Class A Common Stock in multiple transactions. The company states these sales were executed solely to cover tax withholding obligations arising from the vesting and settlement of restricted stock units under a “sell to cover” arrangement.

At what prices were Kevin Feeley’s GeneDx (WGS) shares sold?

The reported sale prices are weighted averages, with trades executed in ranges from $60.93 to $65.61 per share. Each sale line reflects a weighted average within a defined price band, covering multiple individual transactions inside that range on the same day.

How many GeneDx (WGS) shares does the CFO hold after these transactions?

Following the tax-related sales, he beneficially owned 34,580 shares of Class A Common Stock. In addition, he held restricted stock units for up to 93,173 more shares and options to purchase up to 25,906 shares, all vesting according to their respective schedules.

Were the GeneDx (WGS) CFO’s stock sales considered discretionary trades?

The company states the sales were not discretionary trades by the CFO. They were undertaken to satisfy tax withholding obligations tied to RSU vesting through a pre-arranged “sell to cover” mechanism, which automatically sells shares to fund required tax payments.

What are the terms of the GeneDx (WGS) restricted stock units mentioned in the filing?

Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock. Twenty-five percent of the total award vests annually, starting March 26, 2025, assuming continued service; units either vest or are cancelled before vesting.
GeneDx Holdings Corp

NASDAQ:WGS

View WGS Stock Overview

WGS Rankings

WGS Latest News

WGS Latest SEC Filings

WGS Stock Data

1.67B
25.62M
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD